


Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths

14 day average Hospitalizations

1,182 COVID-19 hospitalized patients

10 more patients hospitalized from prior day total (0.9% increase)




7 day Average Deaths

101,854 total confirmed deaths

10 average deaths per day

0.03 deaths per 100K (7-day average)

Deaths per 100K



Average test positivity past 7 days 5.0%, up 0.8% from last week
14 day average hospitalizations have declined to previous lows.
7 day average deaths remain at low levels.

May 18 2023 with data as of May 16, 2023.



<https://covid19.ca.gov/state-dashboard/>

Wastewater data

Show nationwide average

Total results Last 6 months Last 6 weeks

Wastewater: Effective SARS-CoV-2 virus concentration (copies / mL of sewage)



Source: Wastewater data from Biobot Analytics



<https://biobot.io/data/>

Daily new confirmed COVID-19 cases & deaths per million people

7-day rolling average. Limited testing and challenges in the attribution of cause of death means the cases and deaths counts may not be accurate.

LINEAR LOG Split by metric Align axis scales

- Australia
- Belgium
- Brazil
- Canada
- Germany
- India
- Italy
- Japan
- New Zealand
- United Kingdom
- United States



Source: WHO COVID-19 Dashboard

CC BY




COVID-19 cases are low in many countries around the world. There has been a rise and fall in cases in India and Singapore coinciding with an increasing prevalence of XBB.1.16 and XBB.2.3. In the US cases are staying steady and relatively low.

Variant Update: CDC Nowcast Estimate

Weighted and Nowcast Estimates in United States for 2-Week Periods in 1/22/2023 – 5/13/2023

Nowcast Estimates in United States for 4/30/2023 – 5/13/2023

Hover over (or tap in mobile) any lineage of interest to see the amount of uncertainty in that lineage's estimate.



USA				
WHO label	Lineage #	US Class	%Total	95%PI
Omicron	XBB.1.5	VOC	64.0%	59.1-68.6%
	XBB.1.16	VOC	14.3%	11.1-18.1%
	XBB.1.9.1	VOC	9.2%	8.0-10.6%
	XBB.1.9.2	VOC	4.0%	3.2-5.1%
	XBB.2.3	VOC	3.5%	1.9-6.3%
	XBB.1.5.1	VOC	2.4%	1.9-3.0%
	FD.2	VOC	1.8%	0.8-4.0%
	BQ.1.1	VOC	0.3%	0.1-0.5%
	CH.1.1	VOC	0.2%	0.2-0.4%
	XBB	VOC	0.2%	0.1-0.4%
	BQ.1	VOC	0.0%	0.0-0.1%
	BN.1	VOC	0.0%	0.0-0.0%
	BA.5	VOC	0.0%	0.0-0.0%
	BA.2.12.1	VOC	0.0%	0.0-0.1%
	BA.2	VOC	0.0%	0.0-0.0%
	BA.2.75	VOC	0.0%	0.0-0.0%
BF.7	VOC	0.0%	0.0-0.0%	
BA.5.2.6	VOC	0.0%	0.0-0.0%	
Other	Other*		0.0%	0.0-0.0%

XBB.1.16

- WHO variant under monitoring as of March 30th
- • Lineage has rapidly increased in India followed by other Countries. Now rising in the US
- Leading countries (India and Singapore) are showing spike in cases

Compared to XBB.1.5

- XBB.1.16 has two S protein substitutions: E180V and T478R
- Relative effective reproduction number is ~1.2 fold greater
- Paxlovid still works

Other Lineages to watch

- XBB.2.3 – First found in the US and in India. Was growing rapidly in India and Singapore. Now growing rapidly in the US with growth advantage over other sublineages. It has a spike protein mutation that makes it easier to bind to cells – increases infectivity

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid
- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date




Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date

